Tsuyoshi Sasaki

Tsuyoshi Sasaki

Auto-generated profile, based on publicly available information

Tsuyoshi Sasaki

Department of Child Psychiatry, Chiba University Hospital, Chiba, Japan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2015 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
ASAkihiro Shiina
Akihiro Shiina
NKNobuhisa Kanahara
Nobuhisa Kanahara
TSTsuyoshi Sasaki
Tsuyoshi Sasaki
YOYasunori Oda
Yasunori Oda
THTasuku Hashimoto
Tasuku Hashimoto
KHKenji Hashimoto
Kenji Hashimoto
Akihiro Shiina, Nobuhisa Kanahara, Tsuyoshi Sasaki, Yasunori Oda, Tasuku Hashimoto, Tadashi Hasegawa, Taisuke Yoshida, Masaomi Iyo, and Kenji Hashimoto. Clin Psychopharmacol Neurosci 2015;13:62-7. https://doi.org/10.9758/cpn.2015.13.1.62

1 July 2020 in Brain, Behavior, & Immunity - Health
Verified
Journal Article
Open access
ASAkihiro Shiina
Akihiro Shiina
TNTomihisa Niitsu
Tomihisa Niitsu
OKOsamu Kobori
Osamu Kobori
KIKeita Idemoto
Keita Idemoto
THTasuku Hashimoto
Tasuku Hashimoto
MIMasaomi Iyo
Masaomi Iyo
The novel corona virus infection (COVID-19) quickly became a pandemic state. Identifying characteristics of “possible super spreaders”, suggested as a dominant cause of rapid spreading transmission, will help us to design proper prevention strategies. We conducted a nation-wide online survey to investigate the relationship of perception and anxiety levels about COVID-19 to the possible risk behaviors for spread of the virus in Japan. We recruited a total of 4,000 citizens, who responded to the questionnaire including several questions regarding the level of fear and anxiety about COVID-19, infection preventive behaviors and access to media with trust level about the virus as well as some demographic and socioeconomic data during March 27th and 28th, 2020. Thirteen-point-three percent of the participants rated “1” on a nine-point Likert with respect to the knowledge about COVID-19. Ten-point-one percent and 11.7% presented no anxiety of being infected and transmission to others. Ten-point-eight percent showed no worry about symptomatic aggravation. Eight-point-one percent had no serious concern about expanding infection. The distribution of these items was highly correlated with each other. Participants with the low level of knowledge about COVID-19 were likely to less frequently access any information sources and neither trust them. They were less anxious about their health status, and less likely to put precautionary behaviors such as washing hands and avoiding crowded spaces, suggested by statistical analyses. The present study suggests that it is greatly important to enlighten those have no concerns about this crisis of COVID-19 and modify their risk behavior via various ways, in order to prevent and control this viral pandemic. This study was funded by the management grand provided to Chiba University Graduate School of Medicine and the Japan Society for the Promotion of Science KAKENHI grants.

1 August 2015 in Psychiatry Research
Verified
Journal Article
Open access
TSTsuyoshi Sasaki
Tsuyoshi Sasaki
KHKenji Hashimoto
Kenji Hashimoto
YOYasunori Oda
Yasunori Oda
TITamaki Ishima
Tamaki Ishima
TKTsutomu Kurata
Tsutomu Kurata
MIMasaomi Iyo
Masaomi Iyo
Attention Deficit/Hyperactivity Disorder (ADHD) and autism spectrum disorder (ASD) are highly comorbid, and both disorders share executive function deficits. Accumulating evidence suggests that ASD patients have significantly lower peripheral oxytocin (OXT) levels compared with their normal counterparts, and that the repetitive behavior seen in ASD is related to abnormalities in the OXT system. In this study, we investigated whether serum levels of OXT are altered in pediatric patients with ADHD. We measured serum OXT levels: drug naive ADHD (n=23), medicated ADHD (n=13), and age- and sex- matched, neurotypical controls (n=22). Patients were evaluated using the ADHD-RS. Serum levels of OXT in total subjects with ADHD were significantly decreased compared with those of neurotypical controls, and serum levels of OXT in drug naive ADHD patients were significantly lower than those in medicated ADHD patients. Interestingly, there was a significant negative correlation between serum OXT levels and ADHD-RS total scores, as well as ADHD-RS inattentive scores in all ADHD patients. In conclusion, this study suggests that decreased levels of OXT may play a role in the pathophysiology of patients with ADHD and its inherent inattentiveness.

29 October 2015 in Acta Neuropsychiatrica
Verified
Journal Article
Closed access
PDF file
KHKenji Hashimoto
Kenji Hashimoto
TYTaisuke Yoshida
Taisuke Yoshida
MIMasatomo Ishikawa
Masatomo Ishikawa
YFYuko Fujita
Yuko Fujita
TNTomihisa Niitsu
Tomihisa Niitsu
MIMasaomi Iyo
Masaomi Iyo
Objective: Glutamatergic neurotransmission via the N-methyl-d-aspartate (NMDA) receptor is integral to the pathophysiology of depression. This study was performed to examine whether amino acids related to NMDA receptor neurotransmission are altered in the serum of patients with depression.Method: We measured the serum levels of d-serine, l-serine, glycine, glutamate and glutamine in patients with depression (n=70), and age-matched healthy subjects (n=78).Results: Serum levels of d-serine and l-serine in patients with depression were significantly higher than those of healthy controls (p<0.001). In contrast, serum levels of glycine, glutamate and glutamine did not differ between the two groups. Interestingly, the ratio of l-serine to glycine in patients was significantly higher than that of healthy controls (p<0.001).Conclusion: This study suggests that serine enantiomers may be peripheral biomarkers for depression, and that abnormality in the d-serine-l-serine-glycine cycle plays a role in the pathophysiology of depression.

1 May 2014 in Schizophrenia Research
Verified
Journal Article
Open access
HKHiroshi Kimura
Hiroshi Kimura
NKNobuhisa Kanahara
Nobuhisa Kanahara
NKNaoya Komatsu
Naoya Komatsu
MIMinoru Ishige
Minoru Ishige
KMKatsumasa Muneoka
Katsumasa Muneoka
MIMasaomi Iyo
Masaomi Iyo
Dopamine supersensitivity psychosis (DSP) is considered to be one cause of treatment-resistant schizophrenia (TRS). The authors investigated the efficacy of risperidone long-acting injections (RLAI) in patients with TRS and DSP. This is a multicenter, prospective, 12-month follow-up, observational study that included unstable and severe TRS patients with and without DSP. 115 patients with TRS were recruited and divided into two groups according to the presence or absence of DSP which was judged on the basis of the clinical courses and neurological examinations. RLAI was administered adjunctively once every 2weeks along with oral antipsychotics. We observed changes in scores for the Brief Psychiatric Rating Scales (BPRS), Clinical Global Impression-Severity of Illness (CGI-S), Global Assessment of Functioning Scale (GAF), and Extrapyramidal Symptom Rating Scale (ESRS) during the study. Of the assessed 94 patients, 61 and 33 were categorized into the DSP and NonDSP groups, respectively. While baseline BPRS total scores, CGI-S scores and GAF scores did not differ, the ESRS score was significantly higher in the DSP group compared with the NonDSP group. Treatment significantly reduced BPRS total scores and CGI-S scores, and increased GAF scores in both groups, but the magnitudes of change were significantly greater in the DSP group relative to the NonDSP group. ESRS scores were also reduced in the DSP group. Responder rates (≥20% reduction in BPRS total score) were 62.3% in the DSP group and 21.2% in the NonDSP group. It is suggested that DSP contributes to the etiology of TRS. Atypical antipsychotic drugs in long-acting forms, such as RLAI, can provide beneficial effects for patients with DSP. UMIN (UMIN000008487).

1 January 2014 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
TSTsuyoshi Sasaki
Tsuyoshi Sasaki
KHKenji Hashimoto
Kenji Hashimoto
MTMasumi Tachibana
Masumi Tachibana
TKTsutomu Kurata
Tsutomu Kurata
KOKeiko Okawada
Keiko Okawada
MIMasaomi Iyo
Masaomi Iyo
Background: Tipepidine (3-[di-2-thienylmethylene]-1-methylpiperidine) has been used solely as a nonnarcotic antitussive in Japan since 1959. The safety of tipepidine in children and adults has already been established. It is reported that tipepidine inhibits G-protein-coupled inwardly rectifying potassium (GIRK)-channel currents. The inhibition of GIRK channels by tipepidine is expected to modulate the level of monoamines in the brain. We put forward the hypothesis that tipepidine can improve attention deficit/hyperactivity disorder (ADHD) symptoms by modulating monoaminergic neurotransmission through the inhibition of GIRK channels. The purpose of this open-label trial was to confirm whether treatment with tipepidine can improve symptoms in pediatric patients with ADHD. Subjects and methods: This was a 4-week, open-label, proof-of-efficacy pilot study for pediatric subjects with ADHD. Ten pediatric ADHD subjects (70% male; mean age, 9.9 years; combined [inattentive and hyperactive/impulsive] subtype, n=7; inattentive subtype, n=3; hyperimpulsive subtype, n=0) received tipepidine hibenzate taken orally at 30 mg/day for 4 weeks. All subjects were assessed using the ADHD Rating Scale IV (ADHD-RS), Japanese version, and the Das–Naglieri Cognitive Assessment System (DN-CAS), Japanese version. Results: A comparison of baseline scores and 4-week end-point scores showed that all the ADHD-RS scores (total scores, hyperimpulsive subscores, and inattentive subscores) improved significantly (P<0.001). Furthermore, a comparison of baseline DN-CAS total scores and 4-week end-point scores showed a mild trend of improvement (P=0.093). Tipepidine was well tolerated, with no patients discontinuing medication because of side effects. Conclusion: Our pilot study suggests that tipepidine therapy may prove to be an effective alternative treatment for pediatric patients with ADHD. Nonetheless, more detailed randomized, double-blind trials are needed to confirm tipepidine’s efficacy.